Cystoscopy
CYS
Description
"Cystoscopy" test allows doctors to examine the inside of your bladder and urethra using a thin, flexible tube with a camera. It’s often performed to investigate recurring urinary tract infections, blood in the urine, or difficulty urinating. During the procedure, the scope is passed through the urethra to check for swelling, blockages, or unusual growths. Results help pinpoint causes of urinary symptoms and shape treatment plans such as medication, further testing, or minor procedures.
Test Category
Urinary Tract Function
Procedure
Invasive
Sample Type
No biological sample is needed for this test.
Units
Not Applicable
Procedure Category
Scan
Test Group
Endoscopic Procedure Group
Test Group Description
Endoscopic Procedure Group: This group encompasses a range of diagnostic and therapeutic procedures performed using an endoscope, a flexible tube with a camera and light at its tip. These procedures allow healthcare providers to visualize internal organs and tissues, such as the gastrointestinal tract, respiratory system, and urinary tract.
Optimal Range
For All Individuals:
Result: Negative: No abnormalities detected.
Normal Range
For All Individuals:
Result: Negative: No abnormalities detected.
Results That Differ From The Norm (Direct and Indirect Causes)
Abnormal results may indicate:
Bladder cancer
Bladder decompression (relief of pressure within the bladder)
Bladder diverticulum (abnormal pouch in the bladder wall)
Calculi (stones formed in the bladder)
Cysts (fluid-filled sacs)
Cystitis (inflammation of the bladder)
Polyps (abnormal tissue growth)
Prostate cancer
Prostatitis (inflammation of the prostate gland)
Ulcers (open sores on the bladder wall)
Urethral diverticulum (abnormal pouch in the urethra)
Urethral stricture (narrowing of the urethra)
Urethritis (inflammation of the urethra)
Key Reasons For Testing
Bladder Conditions: Diagnoses infections, tumors, or interstitial cystitis by visualizing the bladder lining.
Hematuria Investigation: Identifies sources of blood in urine, such as stones or tumors.
Treatment Planning: Guides biopsies, tumor removal, or stent placements based on findings.
Bladder Outlet Obstruction: Assesses blockages caused by conditions like BPH or urethral strictures.
Monitoring Treatment: Tracks healing or recurrence of bladder conditions.
Urinary Symptoms: Investigates frequent urination, urgency, or pain for underlying abnormalities.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447-461.
[2] Herr HW, Donat SM. Quality control in transurethral resection of bladder tumors. BJU Int. 2008;102(9 Pt B):1242-1246.
[3] Elshal AM, Elkoushy MA, Tholomeus S, et al. Cost effectiveness of blue light cystoscopy with hexaminolevulinate in detection of non–muscle-invasive bladder cancer. Can Urol Assoc J. 2012;6(4):274-281.
[4] Zlatev DV, Altobelli E, Liao JC. Advances in imaging technologies in the evaluation of high-grade bladder cancer. Urol Clin North Am. 2015;42(2):147-157.
[5] Grossman HB, Gomella LG, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial bladder cancer. J Urol. 2007;178(1):62-67.
[6] Droller MJ, Sarosdy MF, Barlogie B, et al. Treatment of superficial bladder cancer with intravesical chemotherapy. Cancer. 1982;49(5):958-966.
[7] Witjes JA, Babjuk M, Gommersall L, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol. 2014;66(5):863-871.
[8] Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate-guided fluorescence cystoscopy reduces recurrence in patients with non–muscle invasive bladder cancer. J Urol. 2010;184(5):1907-1913.
[9] Kassouf W, Traboulsi SL, Schmitz-Dräger BJ, et al. Follow-up in non–muscle-invasive bladder cancer—International Bladder Cancer Network recommendations. Urol Oncol. 2016;34(10):460-468.
[10] Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol.2002;168(5):1964-1970.
[11] Dobruch J, Daneshmand S, Fisch M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69(2):300-310.
[12] Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129.
[13] Lopez-Beltran A, Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and therapeutic implications. Hum Pathol. 2006;37(11):1371-1388.
[14] Witjes JA, Moonen PM, van der Heijden AG. Comparison of hexaminolevulinate-based photodynamic diagnosis and white light cystoscopy in terms of long-term recurrence rate and impact on progression in patients with non–muscle-invasive bladder cancer: results from a prospective, randomized study. J Urol. 2007;178(1):88-92.